activating ligands and -blocking antibodies would have a similar net effect on modulating drug sensitivity, they do indeed share some common cellular effects like EGF-R dimerization (1, 8) , induction of c-fos (12, 13) , and phosphorylation of tyrosine residues on phospholipase C-␥1 (1, 14) that are probably independent of EGF-R kinase activation. These data, coupled with the observations, first, that cisplatin can induce the activity of Srclike kinases (15) and, second, that Src accounts for one of the EGF-R-signaling pathways (16, 17) , suggested to us a mechanistic link between receptor function and cisplatin-induced tumor cell death. Therefore, we have tested the hypothesis that EGF-R-mediated signals modulate cisplatin cytotoxicity in a series of studies with MDA-468 human breast carcinoma cells that exhibit gene amplification at the EGF-R locus. In the present study, we examined by different experimental approaches cisplatin-mediated DNA damage and apoptosis in MDA-468 cells after a reduction in EGF-R expression.
I-EGF binding. Cells were solubilized with a buffer containing 1% Triton X-100, 10% (wt/vol) glycerol, 50 mM HEPES (pH 7.2), 1 mM Na orthovanadate, 50 mM NaF, 1 mM Na iodoacetamide, 1 mM phenylmethanesulfonyl fluoride, and 10 g/mL each of aprotinin, pepstatin, and leupeptin. After sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (7% polyacrylamide gel containing SDS), proteins were transferred to nitrocellulose and probed with 1 g/mL of an anti-EGF-R immunoglobulin (Ig) G1 mouse antibody (Zymed Laboratories, Inc., South San Francisco, CA) followed with a horseradish peroxidase-linked sheep anti-mouse Ig and enhanced chemiluminescence reagent (Amersham Life Science Inc., Arlington Heights, IL). For the determination of EGF-R-binding sites per cell, cells were seeded on 24-well plates and labeled with 0.002-20 nM 125 I-EGF (specific activity, 100 000 cpm/ng) for 4 hours at 4°C in binding buffer (IMEM, 0.1% bovine serum albumin [BSA] , and 20 mM HEPES [pH 7.6]) in the presence of 100-fold unlabeled EGF. Binding data were subjected to Scatchardtype analysis (20) by use of the LIGAND Program (21) (National Institutes of Health, Bethesda, MD).
CAT assay. Aliquots of cell extracts containing 5 g of protein were incubated in a reaction mixture containing [ 14 C]chloramphenicol and acetyl coenzyme A for 2 hours at 37°C, as described previously (22) , by use of an assay kit from Promega Corp. (Madison, WI). CAT activity resulting in the formation of acetylated chloramphenicol was assessed by the separation of the reaction products onto a silica gel plate by thin-layer chromatography.
Colony-forming assays and flow cytometric analysis. For drug sensitivity studies, we used aqueous cisplatin (1 mg/mL in 0.9% NaCl; Bristol-Myers Squibb, Princeton, NJ). Cells (3 × 10 4 ) were plated in 100-mm tissue culture dishes (Falcon) in IMEM-10% FCS. The following day, they were treated for 1 hour with different doses of cisplatin ranging from 0.1 to 30 M. Monolayers were then washed once with drug-free medium and refed IMEM-10% FCS. After 10-14 days, colonies were stained with Giemsa and counted manually. For cell cycle analysis, monolayers were trypsinized 48 hours after drug exposure and stained with 50 g/mL propidium iodide in a hypotonic buffer (1% Triton X-100 and 0.1% Na citrate) for 20 minutes in the dark in the presence of 125 U/mL protease-free ribonuclease (Calbiochem Corp., La Jolla, CA). DNA histograms were analyzed in a FACScan flow cytometer (Becton Dickinson, Mansfield, MA), and offline computer models of the DNA histograms were constructed by use of Modfit software (Verity, Topsham, ME).
DNA cleavage and quantitation by terminal deoxynucleotidyl transferase (Tdt) fluorescence in situ. Internucleosomal DNA fragmentation was detected in pooled adherent and nonadherent cells 48 hours after 1-hour treatment with cisplatin. DNA was isolated as described by Armstrong et al. (23) and electrophoresed in 1.6% agarose gels. A 123-base-pair DNA ladder (Life Technologies, Inc.) was included in the gels to ascertain the size of DNA fragments. Gels were then stained with 0.5 g/mL ethidium bromide, visualized by UV fluorescence, and photographed. Drug-induced breaks in the double-stranded DNA were quantitated as described by Gorczyca et al. (24) with minor modifications (25) . Cell suspensions were fixed in 1% paraformaldehyde for 15 minutes at 4°C and then in 70% ethanol at −20°C for 1 hour. After rehydration in phosphate-buffered saline (PBS)-0.125% BSA, cells were pelleted and resuspended in 1× cacodylate buffer containing 2.5 mM CoCl 2 , 1 nM biotin-16-deoxyuridine triphosphate (dUTP), and 0.1 U Tdt enzyme (Boehringer Mannheim, Indianapolis, IN) for 30 minutes at 37°C. After being washed in PBS-0.125% BSA, cells were resuspended in staining buffer (2.5 g/mL avidin-fluorescein isothiocyanate [FITC] conjugate), 150 mM NaCl, 15 mM Na citrate, and 5% (wt/vol) nonfat dry milk for 30 minutes at room temperature in the dark. FITC-labeled bright cells, representing the apoptotic population, were measured in a FACScan flow cytometer with dye excitation by 15-mW 488-nm laser light. Data on at least 5 × 10 4 events were stored in list mode files for subsequent offline DNA analysis by use of Modfit and WinList software (Verity).
Quantitation of cisplatin uptake and cisplatin-DNA intrastrand adducts. Cells were treated with 10 or 100 M cisplatin for 1 hour. After three washes with ice-cold PBS on ice, monolayers were scraped with rubber policemen, solubilized in 0.1% (vol/vol) Triton X-100 in 0.1 N HCl, and sonicated for 1 minute. The platinum content was measured by atomic absorption spectroscopy, as described previously (26) , by use of a cisplatin standard curve ranging from 0.25 to 5 M. Data were standardized to milligrams of cellular protein (BCA method; Pierce, Rockford, IL). For measurement of intrastrand cisplatin-DNA adducts, tumor cell DNAs were isolated by a nonorganic extraction procedure (27) and assayed in a cisplatin-DNA dissociation-enhanced fluoroimmunoassay, as previously described (28) . Briefly, the assay was performed using microtiter plates coated with 0.3 ng of a cisplatin-DNA standard (90 pmol cisplatin/g DNA [three adducts per 100 nucleotides or 3% modification]). Plates were blocked with FCS for 60 minutes at 37°C. Each sample was assayed at least twice in triplicate wells; each well contained 12-15 g of sample DNA or standard cisplatin-DNA. A rabbit antiserum raised against 4.3% (4.3 adducts per 100 nucleotides) modified cisplatin-DNA (29) was used as primary antibody (1:120 000 in 1% FCS in PBS), and biotinylated goat anti-rabbit IgG (1:20 000 in 1% FCS in PBS; Vector, Burlingame, CA) was used as secondary antibody. Subsequent incubations were performed first in europium-labeled streptavidin (1:2500) in Wallac assay buffer and then in Wallac enhancement solution (Wallac, Gaithersburg, MD). Fluorescence was read at 614 nm by a dissociationenhanced fluoroimmunoassay fluorometer (Wallac). Calf thymus DNA modified to 300 fmol cisplatin/g DNA was used as standard. The average 50% inhibition ± standard deviation determined from standard curves generated from 40 different experiments was 0.59 ± 0.04 pmol platinum. By use of 15 g of DNA per microtiter well, the detection limit of the assay was 4 fmol platinum/g DNA.
Experiments in athymic mice. Four-to 6-week-old female athymic mice (Harlan Sprague-Dawley, Inc., Madison, WI) were inoculated subcutaneously slightly caudal to the forelimb with 10 7 MDA-468/p-CAT cells or with MDA-468/AS-EGFR cells. On days 7 and 14 after tumor cell inoculation, the mice received 200 g cisplatin in a 0.2-mL volume or 0.2 mL PBS intraperitoneally via a 26-gauge needle. Tumor diameters were measured with calipers, and tumor volume in cubic millimeters was calculated as volume ‫ס‬ (short diameter) 2 × long diameter/2. Animal care was conducted in accord with institutional accredited guidelines.
Results

Expression of EGF-R Antisense RNA
To study the role of EGF-R in the cellular response to cisplatin, we transfected the MDA-468 cell line, which exhibits gene amplification at the EGF-R locus (30) , with a 4.1-kb antisense RNA representing the entire coding region of the EGF-R cDNA (18) and a pSV2neo vector. Controls were transfected with the p-CAT vector (31) and pSV2neo. Single-cell G418-resistant cell lines were expanded and tested for EGF-R content and 125 I-EGF binding. By western blot analysis, EGF-R protein was drastically reduced in all MDA-468/AS-EGFR clones, whereas control (MDA-468/p-CAT) clones exhibited EGF-R protein levels similar to those of parental cells (Fig. 1 ). Scatchard analysis of 125 I-EGF binding to parental cells and all MDA-468/p-CAT clones showed 1.3 × 10 6 or more EGFbinding sites per cell with a dissociation constant of 0.5-0.7 nM. All MDA-468/AS-EGFR clones exhibited 3 × 10 4 or fewer EGF-binding sites per cell (data not shown). To confirm that both the p-CAT and pSV2neo vectors were integrated by the MDA-468/p-CAT control clones, cells were tested for CAT activity. All G418-resistant control clones exhibited CAT activity (data not shown).
Cisplatin-Mediated Cytotoxicity and Cell Cycle Arrest
Cisplatin sensitivity was tested in an adherent colony-forming growth assay 10 days after a 1-hour exposure to pharmacologically achievable doses of drug ranging from 0.1 to 30 M. A representative experiment is shown in Fig. 2 . MDA-468/p-CAT clones and MDA-468 parental cells were markedly inhibited by low concentrations of cisplatin, whereas MDA-468/AS-EGFR clones were relatively resistant with a 1-hour IC 50 (i.e., concentration of drug required for 1 hour to achieve 50% cell kill) of 25 M or higher ( Table 1 ). The 1-hour cisplatin IC 50 for several low-and high-EGF-R-expressing clones tested is summarized in Table 1 . Similar differences in sensitivity depending on EGF-R levels were encountered with the cisplatin analogue carboplatin but not with doxorubicin, etoposide, and paclitaxel (data not shown).
The MDA-468/AS-EGFR98 and MDA-468/p-CAT6 clones were selected for cell cycle analysis and for further mechanistic studies. Consistent with the notion that cisplatin-induced cell death is preceded by a block in G 2 (32, 33) , 92% of MDA-468/ p-CAT6 cells were arrested in G 2 phase 48 hours after cisplatin treatment, as shown by flow analysis of propidium iodidelabeled DNA (Fig. 3) . By 72 hours, the cells detached, which agrees with the cytotoxicity data given above. Conversely, after a transient increase in the number of cells in G 2 at 24 hours, MDA-468/AS-EGFR98 cells overcame this block by 48 hours after drug exposure (Fig. 3) . Of note, the percentages of cells in S and G 2 phases were 38% and 19%, respectively, in untreated MDA-468/AS-EGFR98 cells and 27% and 21%, respectively, in MDA-468/p-CAT6 cells, which suggests that the difference in drug sensitivity was not due to an intrinsic difference in the proliferation rate between both clones.
Cisplatin-Induced Apoptosis and Breaks in Double-Stranded DNA
We next examined whether the marked difference in 1-hour IC 50 was due to a difference in the ability of these cells to undergo programmed cell death following cisplatin-mediated DNA damage (34) . DNA was extracted from several MDA-468/ p-CAT (vector) and MDA-468/AS-EGFR clones 48 hours after 1-hour treatment with 10 M cisplatin and resolved in agarose gels. Cisplatin-treated DNA from all MDA-468/p-CAT clones exhibited a pattern of internucleosomal fragmentation characteristic of apoptotic cells (35) . This pattern of DNA cleavage was undetectable in three of three MDA-468/AS-EGFR clones (Fig.  4, A) . To quantitate drug-induced double-stranded DNA breaks, cells were made permeable with paraformaldehyde and labeled with biotinylated dUTP in the presence of Tdt enzyme. Biotinlabeled DNA breaks were then labeled with FITC-conjugated avidin and quantitated by flow cytometry. Forty-eight hours after exposure to 10 M cisplatin for 1 hour, 45% of MDA-468/ p-CAT6 cells but only 4% of MDA-468/AS-EGFR98 cells exhibited FITC labeling in situ, which confirms the DNA cleavage results (data not shown).
Studies With MDA-468 TP-40 Cells
To ensure that the effect of EGF-R loss on cisplatin response was not due to a transfection artifact, we selected an MDA-468 subline in the presence of a TGF-␣-Pseudomonas exotoxin A fusion protein, TP-40 (19) 468/AS-EGFR clones (data not shown). Similar to that for the low-EGF-R-expressing clones, the 1-hour IC 50 of cisplatin in MDA-468 TP-40 cells was greater than 30 M (65% survival at 30 M cisplatin) and, when tested simultaneously with wild-type parental MDA-468 cells, failed to exhibit DNA laddering in agarose gels after drug treatment (Fig. 4, B) .
Cisplatin Sensitivity of Nude Mouse Xenografts
Once we established that, depending on the EGF-R level, these cells exhibited a marked difference in their response to cisplatin in vitro, we confirmed this difference in a nude mouse model. Similar to the low-EGF-R-expressing variants reported by Filmus et al. (30) , all three MDA-468/AS-EGFR clones (Table 1) formed tumors in athymic mice. MDA-468/AS-EGFR98 or MDA-468/p-CAT6 cells were inoculated subcutaneously into female nude mice and were allowed to reach a tumor size of approximately 200 mm 3 (7 days). At that time and on day 14 after tumor inoculation, animals were inoculated with either PBS or 200 g cisplatin in PBS intraperitoneally. Both untreated MDA-468/AS-EGFR98 and MDA-468/p-CAT6 tumors grew at a comparable rate. However, five of five high-EGF-R-expressing MDA-468/p-CAT6 cell-induced tumors were eradicated by cisplatin therapy, whereas the growth of MDA-468/AS-EGFR98 cell-induced tumors was transiently inhibited but the tumors were not eradicated, thus confirming relative drug resistance in vivo (Fig. 5) . Drug-induced toxicity was undetectable in all animals.
Intracellular Cisplatin Accumulation and Cisplatin-DNA Adducts
We next measured total intracellular drug accumulation by atomic absorption spectroscopy (26) of whole cell lysates immediately after a 1-hour incubation with 10 and 100 M cisplatin. At both doses, we were unable to detect significant differences in drug uptake between MDA-468/p-CAT and MDA-468/AS-EGFR clones and thus were not able to explain the large difference in cisplatin sensitivity between both types of cells (Fig. 6) .
Finally, we measured the formation and time course of intrastrand G-G and A-G cisplatin-DNA adducts in tumor cell DNA with a cisplatin-DNA dissociation-enhanced fluoroimmunoassay method described in the ''Materials and Methods'' section. These adducts represent the majority of cisplatin-induced DNA lesions and are considered critical for the drug's cytotoxic effect (36, 37) . The formation and persistence of these lesions in DNA are inversely proportional to the efficacy of cellular mechanisms that recognize and repair cisplatin-damaged DNA (38, 39) . MDA-468/p-CAT and MDA-468/AS-EGFR cells were treated with 100 M cisplatin for 4 hours, and their DNA was harvested for subsequent cisplatin-DNA intrastrand adduct measurements by the dissociation-enhanced fluoroimmunoassay method. In some cases, cells were washed and refed, and cultures were maintained at 37°C for 4 additional hours prior to DNA harvest. At both times, immediately after drug exposure and/or after the 4-hour post-wash period, there were more adducts in the high-EGF-R-expressing MDA-468/p-CAT6 and MDA-468/p-CAT11 clones than in the MDA-468/AS-EGFR46 and MDA-468/AS-EGFR98 clones (Table 2) , which is consistent with the marked difference in the 1-hour IC 50 of cisplatin depicted in Table 1 . 25.0 *High-and low-EGF-R-expressing cell lines were sparsely plated in triplicate 100-mm tissue culture dishes as indicated in the ''Materials and Methods'' section. Giemsa-stained colonies were counted manually 10-14 days after a 1-hour treatment with 0.1, 0.3, 1, 3, 10, or 30 M cisplatin. Standard deviations were <10%.
†The approximate 1-hour drug IC 50 (i.e., concentration of drug required for 1 hour to achieve 50% cell kill) was calculated from the growth inhibition doseresponse curve. Clones with an IC 50 of >30 M exhibited under 50% cell kill at the maximal tested concentration. ) were plated in 100-mm dishes in improved modified minimum essential medium (IMEM) and 10% fetal calf serum. After 24 hours, cells were treated for 1 hour with the indicated doses of cisplatin, washed free of drug, and refed with IMEM-10% FCS. After 10 days, colonies were stained with Giemsa and counted manually.
Discussion
Using the MDA-468 human breast cancer cell line, which exhibits a functional autocrine TGF-␣/EGF-R pathway (7) and EGF-R gene amplification (30), we have demonstrated that a critical level of EGF-R signaling is required for cisplatinmediated programmed cell death. Several clones transfected with an antisense EGF-R cDNA as well as a subline selected for very low EGF binding (<5 × 10 3 binding sites/cell) by an approach other than gene transfer, all with a greater than 40-fold lower EGF-R, consistently exhibited resistance to the DNAdamaging cisplatin in vitro and when established in athymic mice. In adherent colony-forming assay, the difference in 1-hour IC 50 between high-and low-EGF-R-expressing cells approached two logarithms in magnitude. At cisplatin concentrations well above a lethal dose for cells with high EGF-R levels, druginduced G 2 arrest and DNA fragmentation were undetectable in isogenic cells with low EGF-R levels. This difference in drug sensitivity appeared specific for cisplatin, could not be accounted for by a different proliferative capacity of the cells (40) or tumorigenicity, and was not seen with the anticancer agents doxorubicin, etoposide, and paclitaxel, all of which damage DNA by alternative mechanisms (41) . With the use of an antiserum that recognizes intrastrand G-G and A-G cisplatin-DNA adducts (29), a higher level of adducts was detected in the high-EGF-R-expressing cells than in the low-EGF-R-expressing cells. These adducts represent the most prevalent (>90%) type of cisplatin-induced DNA lesion (36, 37) and, in leukocytes from testicular and ovarian cancer patients receiving cisplatin, are associated with a favorable clinical response to therapy (42) . Taken together, these data support an inhibitory effect of EGF-R signal transduction on the repair of cisplatin-mediated DNA damage, which, in turn, facilitates programmed tumor cell death. However, since the difference in adduct levels between cells with high and low EGF-R levels ( Table 2) does not account for the differences in 1-hour IC 50 (Table 1) , the data also suggest a direct effect of EGF-R signals on the apoptotic response to cisplatin independent of direct DNA damage.
Several published data are consistent with our results. Christen et al. (9) reported cisplatin sensitization of 2008 ovarian carcinoma cells by EGF that was independent of EGF-induced mitogenesis or altered intracellular drug accumulation. Of note, cisplatin-resistant 2008/C13 cells exhibited threefold fewer EGF-binding sites per cell with a lower ligand-binding affinity compared with parental drug-sensitive 2008 cells, whereas their sensitivity was not altered by EGF treatment (9) . ME-180 cervical carcinoma cells selected for resistance to tumor necrosis factor exhibited higher levels of constitutively phosphorylated EGF-R and became cisplatin hypersensitive relative to unselected parental cells (43) . EGF treatment further enhanced cisplatin sensitivity of ME-180 cells, while it decreased unscheduled DNA synthesis after drug treatment (43) . Furthermore, agonistic antibodies against the extracellular domain of erbB-2 (44), a homologous receptor of the EGF-R family, enhanced cisplatin-mediated cytotoxicity probably by inhibiting DNA repair (as measured by unscheduled DNA synthesis) and the formation and removal of intrastrand d-(pGpG) cisplatin-DNA adducts (27, 45) . In addition, when selected for (12-fold) cisplatin resistance, SKOV-3 ovarian tumor cells, which exhibit erbB-2 gene amplification, contained sevenfold less erbB-2 than sensitive parental cells (46) . On the basis of these studies, one could argue that high EGF-R levels in tumors may predict for a greater likelihood of a clinical response to cisplatin, as supported by the previously reported activity of this drug against squamous cell cancers of the upper aerodigestive tract (41) . A large proportion of these tumors overexpresses EGF-R (4). At first glance, this speculation may appear to disagree with the previously reported association between EGF-R overexpression and poor patient prognosis (4). It should be noted, however, that published epi- 26.0 ± 14.4 ND *The indicated cell lines were treated with 100 M cisplatin for 4 hours. DNA was collected immediately after this 4-hour incubation (0 h column). In some cases, monolayers were washed and replenished with drug-free improved modified minimal essential medium (IMEM) and 10% fetal calf serum prior to DNA harvest. Cisplatin-DNA adducts were then measured by the cisplatin-DNA dissociation-enhanced fluoroimmunoassay method, as described in the ''Materials and Methods'' section.
†Each data point represents the mean ± standard error in femtomoles of cisplatin-DNA intrastrand adducts standardized to micrograms of DNA (10 8 cells) from four assays of the same sample on different days. ND ‫ס‬ not done.
‡P ‫ס‬ .004 (MDA-468/p-CAT11 versus both MDA-468/AS-EGFR clones, two-sided Student's t test).
§P ‫ס‬ .11 (MDA-468/p-CAT6 versus MDA-468/AS-EGFR98, two-sided Student's t test). 6 . Intracellular accumulation of cisplatin. High-epidermal growth factor receptor (EGF-R)-expressing (p-CAT6 and p-CAT11) and low-EGF-Rexpressing (AS-EGFR46 and AS-EGFR98) transfected MDA-468 clones were treated for 1 hour with 10 or 100 M cisplatin in improved modified minimal essential medium (IMEM) and 10% fetal calf serum. After two washes, cell lysates were prepared as described in the ''Materials and Methods'' section, and platinum (Pt) content was measured by atomic absorption spectroscopy. Each column represents the mean ± standard deviation standardized to total milligrams of cellular protein from three 100-mm dishes.
demiologic surveys have in general studied diagnostic (pretherapy) tissues but not recurrent metastatic tissues in which EGF-R content could have been altered by a therapeutic intervention including cisplatin. Future studies of EGF-R expression in tumor recurrences after an initial response to cisplatin may shed light on this speculation.
All the antisense clones exhibited a more than 40-fold decrease in EGF-R. Therefore, whether there is a critical threshold level of EGF-R and/or downstream signal(s) for cisplatinmediated apoptosis to occur is unclear from these results. Of note, MDA-468/AS-EGFR clones 98, 46, and 32 were neither stimulated to proliferate by 1-10 ng/mL TGF-␣ nor inhibited by anti-EGF-R antibodies, which suggests total functional inactivation of the EGF-R pathway in these cells. Interestingly, receptor blockade of EGF-R-overexpressing tumor cells with antibodies against the receptor's extracellular domain enhances rather than compromises cisplatin response (10, 11) . These data suggest that cellular effects induced by anti-EGF-R-blocking antibodies (8, 13, 14) may be involved in drug sensitization and do not necessarily contradict the results with our alternative antisense approach.
Accordingly, one possible interpretation of our data is that basal signals downstream the EGF-R are necessary for cisplatin response. This interpretation is also supported by the following findings: 1) Cisplatin activates Src-like protein tyrosine kinases (15), 2) c-Src is modulated by EGF-R signals (16, 17, 47, 48) , and 3) overexpression of v-Src sensitizes Rat-6 embryo fibroblasts to cisplatin (49) . In cells with a high level of auto-activated EGF-R, these signaling pathways are possibly already primed, thus requiring less cisplatin to progress to apoptosis. The MDA-468 cells utilized in our study do exhibit an operative TGF-␣/EGF-R autocrine loop, as is supported by their sensitivity to anti-EGF-R-blocking antibodies (7), the predominant membrane localization and constitutive phosphorylation of phospholipase C-␥1 (an EGF-R cellular substrate) without added growth factor (50) , and the basal level of EGF-R tyrosine phosphorylation in the absence of exogenous ligand that can be unmasked by the protein tyrosine phosphatase inhibitor vanadate (Arteaga CL: unpublished data). These putative EGF-R-modulated biochemical/ molecular events necessary for the cellular response to cisplatin will require further study.
Another potential interpretation (not exclusive of the former) of our results is that, in cells with high levels of EGF-R, the receptors are a direct cellular target for cisplatin, as suggested by the reported reduction of EGF-binding sites and ligand affinity in MCF-7 breast cancer cells following cisplatin treatment (51) . However, in preliminary experiments, the receptor in vitro kinase activity from untreated and cisplatin-treated MDA-468 cells (as measured by [ 32 P]␥-adenosine triphosphate incorporation onto EGF-R immunoprecipitates) is identical, thus arguing against the latter speculation (Arteaga CL: unpublished data).
Overexpression of other oncogenes like E1A, H-ras, and cmyc (52) (53) (54) has been shown to enhance the cellular susceptibility to apoptosis induced by DNA-damaging anticancer agents under some conditions. These studies did not include cisplatin. However, the agents utilized, like cisplatin, also induce apoptosis and G 2 arrest (34) . Transfection studies in low-EGF-R-expressing epithelial cells to test whether EGF-R overexpression results in enhanced sensitivity to cisplatin are currently in progress. The experimental approach used in this study was opposite that utilized in the above-mentioned overexpression studies (52-54), since we chose to eliminate EGF-R signaling to decrease rather than to enhance drug sensitivity. Nevertheless, our results are still consistent with the notion that overexpression of growth-regulatory signals in tumor cells may indeed lower the threshold for drug-mediated programmed cell death (55), a scenario with significant clinical implications.
